Kornimate/medical-research-clean huggingface dataset:
adjunctive steps for disinfection of teeth with primary endodontic infections

Conditions: Periapical Periodontitis; Bacterial Infections

Summary: this study aims to evaluate an endodontic treatment protocol using adjunctive steps for disinfection of teeth with primary endodontic infections.

the success of endodontic treatment in teeth with necrotic pulp and apical periodontitis depends on the reduction of viable microorganisms of root canals by endodontic disinfection procedures. this study aims to evaluate by molecular methods the effect of different disinfection procedures on reduction, diversity and microbial metabolic activity. patients with necrotic pulps and apical periodontitis in single-rooted teeth will be selected. microbiological samples will be taken from root canals after access cavity (s1), after chemomechanical preparation with reciproc system and 2.5% naocl (s2), after irrigant activation using the xp-endo finisher instrument (s3a) and ultrasonic activation (s3b); and after intracanal medication with calcium hydroxide for 14 days (s4), followed by 2nd-visit root canal preparation (s5). dna and rna will be extracted from root canal samples, and complementary dna (cdna) synthetized using reverse transcription reaction. the effect of treatment protocols on total microbiota levels will be determined by dna-based quantitative polymerase chain reaction (qpcr) using universal primers for bacteria domain. rna of root canal samples will be used to determine the diversity of metabolically active microbiota by reverse transcriptase reaction (rt), followed by amplification (pcr) and high throughput sequencing of the hypervariable region v4-v5 of 16s rrna gene. the metabolic activity of the most prevalent species / taxa will be calculated by rrna- and dna-based molecular methods. ratios between rrna and dna levels will be calculated to search for active bacteria (rrna/dna ≥ 1) in root canal samples. data will be analyzed by statistical tests, with 5% significance level.

Eligibility criteria:
inclusion criteria: * teeth with necrotic pulps and asymptomatic apical periodontitis exclusion criteria: * patients who had received antibiotics during the previous 3 months or had any general disease, * teeth that could not be properly isolated with rubber dam, * non-restored teeth, * periodontal pockets depths greater than 4 mm, * previous endodontic treatment, * open apex, * crown/root fracture * root resorption or calcifications.

Keywords: periapical periodontitis bacterial infections root canal preparation calcium hydroxide real-time polymerase chain reaction rna-directed dna polymerase
peptide vaccine and temozolomide for metastatic melanoma patients

Conditions: Malignant Melanoma

Summary: the aim of the study is to assess if treatment with ido/survivin peptide vaccine can enhance the efficacy of temozolomide chemotherapy in patients with metastatic malignant melanoma.

secondarily to studying the efficacy of the treatment; the investigators examine if treatment with ido/survivin peptide can induce a measurable cellular t-cell response when the vaccine is given in combination with temozolomide treatment for melanoma patients.

Eligibility criteria:
inclusion criteria: 1. histological verified malignant melanoma 2. metastatic disease (brain metastasis allowed if asymptomatic) 3. evaluable disease recording to recist v. 1.1 4. age \> 18 years 5. performance status, ps=0, ps=1 or ps=2 6. life expectancy \> 3 months 7. adequate bone marrow function 8. leucocyte count \> 2,5 \* 109/l 9. granulocyte count \> 1,5 \* 109/l 10. thrombocyte count \> 100 \* 109/l 11. creatinine \< 2,5 \* unl 130 micromol/l 12. adequate liver function 13. asat \< 100 u/l 14. bilirubin \< 300 u/l 15. s-hcg negative (fertile women) 16. written informed consent 17. inclusion at least 4 weeks after major abdominal surgery 18. if radiotherapy for brain metastases prior to inclusion, then progressive disease proven by new brain mr-scan before inclusion exclusion criteria: 1. treatment with immune suppressors (ie. prednisone) not allowed 2. other malignancies 3 years prior to inclusion except benign skin lesions 3. severe medical condition, severe asthma, severe col, severe heart- or diabetic disease 4. acute/chronic infection with hiv, hepatitis or tuberculosis 5. known severe allergic reactions 6. former anaphylactic reactions 7. active autoimmune diseases 8. pregnant or nourishing women 9. psychiatric disease resulting in non-compliance 10. known allergic reactions towards montanide, imiquimod, temozolomide or leukine 11. simultaneously treatment with other experimental drugs patients cannot be treated with chemotherapy, radiotherapy (except locally) or immunotherapy 14 days within inclusion.

Keywords: indeolamine 2,3 dioxygenase survivin montanide imiquimod gmcsf
disturbed structural connectivity of frontostriatal and frontoparietal networks in adults with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: attention deficit/hyperactivity disorder (adhd) is a common, impairing, childhood onset neuropsychiatric disorder with executive dysfunctions. the adhd symptoms and executive deficits may last to adulthood. our previous studies, like western results, have shown that children with adhd have disrupted microstructural integrity of frontostriatal fiber pathways and impaired brain activity in frontoparietal network. however, there is lack of data with regards to whether adults with adhd also demonstrate structural and functional disconnectivity of frontostriatal and frontoparietal networks as compared to healthy controls without adhd in asian population and no study has been done to correlate a wide range of executive functions with the connectivity of these two networks. specific aims: 1. to compare the executive functions, and structural and functional connectivity in frontostriatal and frontoparietal circuitries between adults with adhd and healthy controls without adhd; 2. to correlate the data from structural and functional connectivity, executive functions, and adhd core symptoms stratifying by the adhd and controls; and 3. to explore other circuitries that may involve in adhd by using whole brain tractography analyses.


Eligibility criteria:
inclusion criteria: * subjects aged 18-45, who have clinical diagnosis of a adhd according to the dsm-iv criteria. exclusion criteria: * the subjects will be excluded from the study if they meet any of the following criteria: (1) comorbidity with diagnoses of autism spectrum disorder, schizophrenia, schizoaffective disorder, delusional disorder, other psychotic disorder, organic psychosis, schizotypal personality disorder, bipolar disorder, depression, severe anxiety disorders or substance use; (2) with neurodegenerative disorder, epilepsy, involuntary movement disorder, congenital metabolic disorder, brain tumor, history of severe head trauma, and history of craniotomy; (3)with visual or hearing impairments, or motor disability which may influence the process of mri assessment; and (4) full-scale iq lower than 80.

Keywords: adult adhd diffusion spectrum imaging resting-state fmri frontostriatal circuitries frontoparietal circuitries executive function
comparison of autologous chondrocyte implantation versus mosaicoplasty: a randomized trial

Conditions: Knee Chondral or Osteochondral Defect

Summary: numerous surgical techniques have been developped for the treatment of chondral and osteochondral defects of the knee. among those techniques autologous chondrocyte transplantation (act) was promising but have potential drawbacks. a novel development by tbf is available. the aim of this randomized trial is to compared this new act technique to mosaicoplasty. final outcomes were measured at 2 years using clinical evaluation scoring system (international knee documentation committee), mri and arthroscopy with biopsy. 64 patients are needed to detect a mean ikdc difference of at least 15 points with 90% power at a 5% alpha level. twelve surgical centers in france are involved.


Eligibility criteria:
inclusion criteria: * isolated femoral osteochondral lesion * aged 18 to 50 * grade 3 or 4 lesion (icrs) sized 2,5 cm2 to 7,5 cm2. * ikdc score below 55 exclusion criteria: * pregnancy * allergy * arthrosis * varus or valgus angle greater than 10° * acl laxity * severe chronic disease * bmi \> 30 kg/m2 * hiv, b or c hepatitis

Keywords: knee chondral defect osteochondral defect
improvement of physical and physiological parameters in menopausal or post-menopausal celiac women

Conditions: Celiac Disease; Diet, Gluten-Free; Exercise; Resistance Training; Quality of Life; Body Composition

Summary: celiac disease (cd) is an immunological disorder that mainly affects the small intestine, generating an inflammatory process in response to the presence of gluten (a protein). autoimmune diseases are part of a group of diseases that are difficult to diagnose without a specific protocol or consensus to detect them due to the number of symptoms and diseases with which it has a relationship. the incidence of cd in spain -according to data from the rest of the european economic community, since there is no study on incidence in spain- is assumed to be approximately 1 per 100 live births. it is more frequent in women, with a 2:1 ratio. the only treatment consists of a strict gluten-free diet for life. this results in the disappearance of symptoms, normalization of serology and recovery of intestinal villi. failure to follow the diet can lead to important complications which, especially in adulthood, can manifest themselves in the form of osteopenia, osteoporosis and a high risk of neoplasms in the digestive tract, mainly. the main objective is to achieve a physical and physiological improvement in menopausal or post-menopausal celiac women. the specific objectives will be to know the influence of a dietary-nutritional program combined with physical exercise in menopausal or post-menopausal celiac women on: * physical condition (strength, endurance, functional autonomy...). * body composition. * psychological aspects. * physiological parameters (heart rate, maximum oxygen consumption, blood analysis...).


Eligibility criteria:
inclusion criteria: * women * over 40 years old * menopausal or post-menopausal women * women with celiac disease (in the case of the experimental groups) exclusion criteria: * men * women of childbearing age * women \< 40 years old * failure to sign informed consent form
study of ceftazidime-avibactam blood concentrations in intensive care unit patients with renal failure requiring continuous dialysis

Conditions: Renal Failure; Bacterial Infections; Critical Illness

Summary: the study's primary objective is to determine plasma and dialysis fluid concentrations in patients prescribed ceftazidime-avibactam as the standard treatment for their infection and requiring continuous venovenous hemodiafiltration (cvvhdf) as part of the standard treatment for acute or chronic renal failure. secondarily, the study will evaluate the pharmacokinetics of ceftazidime-avibactam in these patients on cvvhdf. the study will also determine if the prescribed dose meets pharmacodynamic targets.


Eligibility criteria:
inclusion criteria: * adults \> 18 years of age * patients requiring continuous renal replacement therapy (crrt) due to acute or chronic renal failure * documented or suspected infection requiring a prescription for ceftazidime-avibactam exclusion criteria: * patients on crrt \< 24 hours * patients on ceftazidime-avibactam \< 24 hours * patients unable to remain on crrt for 32 hours continuously without clotting
adagrasib in combination with tno155 in patients with cancer (krystal 2)

Conditions: Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease

Summary: this study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of mrtx849 in combination with tno155 in patients with advanced solid tumors that have a kras g12c mutation.

this study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of mrtx849 in combination with tno155 in patients with advanced solid tumors with a kras g12c mutation. mrtx849 is an orally available small molecule inhibitor of kras g12c and tno155 is a selective, orally bioavailable allosteric inhibitor of wild-type shp2. this study was terminated prior to phase 2 initiating. only phase 1 of the study was conducted.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of a solid tumor malignancy with kras g12c mutation (phase 2 must be either non-small cell lung cancer or colorectal cancer) * unresectable or metastatic disease * no available treatment with curative intent * adequate organ function exclusion criteria: * history of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow * other active cancer * cardiac abnormalities

Keywords: kras g12c non-small cell lung cancer colorectal cancer colon cancer metastatic cancer pancreatic cancer nsclc shp2 advanced solid tumors
telerehabilitation in lung surgery patients

Conditions: Lung Cancer; Physiotherapy

Summary: in this study, providing access to physiotherapy applications by telerehabilitation method and the effectiveness of this application will be examined for patients who have undergone lung surgery in the early postoperative period during the pandemic process in which social isolation continues.

* patients who meet the inclusion criteria and agree to participate in the study will be included in the study. * patients diagnosed with lung cancer and underwent thoracotomy will be randomly divided into telerehabilitation group (tgr) and control (kg) groups. * before the operation, enlightened and signed consent will be obtained from the cases, the first evaluations of the patients in both groups will be made and the first exercise training will be given to the telerehabilitation group. * the study group will be followed up every day during their hospitalizations and the final tests of both groups will be made before discharge. long-term follow-up will be carried out in the 1st month and 3rd month after discharge.

Eligibility criteria:
inclusion criteria: * having a smart phone and capable of making video calls, * planned to be operated with thoracotomy or videothoracoscope, * staged between ia and iiib with clinical staging, * with proven lung tumor (if ac diagnosis is not confirmed after frozen or wedge, the patient will be excluded from the study), * patients with no cardiac disease (asa ii or better) that affects their quality of life. exclusion criteria: * having a cardiac disease that affects the quality of life, * serious cognitive problems and presence of psychiatric diseases, * presence of physical limitations (vision, hearing impairment, orthopedic problems).

Keywords: exercise videoconference lung cancer surgery postoperative chest physiotherapy telerehabilitation
examining the effectiveness of the faces adolescent sbirt intervention

Conditions: Adolescent Health Services; Adolescent Behavior

Summary: the study will utilize a stepped wedge cluster randomized design to examine the effectiveness of the full faces (facilitating change for excellence in sbirt) adolescent sbirt change package. primary care providers will be randomized as to when they receive training and begin delivery of faces with their 12 to 17 year old patients, which includes targeted feedback based on the patient's endorsed substance use level on the s2bi screening instrument.

the study will utilize a stepped wedge cluster randomized design to examine the effectiveness of the full faces (facilitating change for excellence in sbirt) adolescent change package for 12 to 17 year old primary care patients. primary care providers at two rural federally qualified health centers in new mexico and tennessee will be randomized as to when they receive training and begin delivering faces to their adolescent patients. faces includes targeted feedback based on the patient's endorsed substance use level on the s2bi screening instrument. study participants will complete a baseline and follow-up assessment 3-months post study recruitment.

Eligibility criteria:
inclusion criteria: * ages 12 to 17 years, inclusive * registered patient at one of the participating fqhcs * able and willing to provide informed consent exclusion criteria: * inability to comprehend the assent form * parent/guardian declines consent

Keywords: sbirt
adapting and testing a novel digital health tool (prevent) to improve health behavior counseling and cardiovascular health in rural primary care clinics

Conditions: Obesity; Cardiovascular Diseases

Summary: the focus on this application is low-income, rural patients, since cardiovascular disease (cvd) prevalence is 40% higher among rural than urban residents. health behavior counseling and follow-up care are required for patients with an elevated body mass index who have increased risk for cvd. counseling is most effective when developed with, and tailored to, the patient and offered with resources that support healthy food intake and physical activity. resource referral and follow-up is particularly important in rural low income residents who often have more severe social needs that impede healthy behaviors. the proposed research will leverage the candidate's digital health tool (prevent) for healthcare teams to use within the clinic visit. prevent visually displays patient-reported and electronic health record (ehr) data to facilitate counseling and deliver tailored physical activity and healthy food intake goals and resources. prevent may improve the quality of required care and promote cardiovascular health equity. this research will: 1) collaborate with rural and clinic partners to modify and integrate the prevent tool for low-income, rural patients with obesity (aim 1); and 2) conduct a pilot pragmatic clinical trial of prevent to optimize feasibility, acceptability, appropriateness, and potential health equity impact.


Eligibility criteria:
inclusion criteria: * aged 18-64 years at baseline * low-income (household income \<200% poverty) * a bmi ≥ 30 * receiving care from the missouri highlands. * ability to understand and willingness to sign an irb approved written informed consent document (or that of legally authorized representative, if applicable).
compact 2 - combining plasma-filtration and adsorption clinical trial 2

Conditions: Shock, Septic

Summary: the study objective is to clarify whether the application of high doses cpfa (coupled plasma-filtration adsorption) in addition to the current clinical practice is able to reduce hospital mortality in septic shock patients in intensive care unit (icu).

septic shock is a life-threatening clinical condition characterized by cardiovascular failure as a consequence of infection. septic shock frequently causes multi-organ failure in the icu. for this reason the extracorporeal therapies for the treatment of renal failure have become widespread in the icu and, at the same time, new extracorporeal depurative techniques have been developed for the removal of inflammatory mediators. one of these techniques is cpfa (coupled plasma-filtration adsorption) that uses a sorbent once the separation between plasma and blood has been obtained with a plasma filter. the study objective is to clarify whether the application of high doses cpfa in addition to the current clinical practice is able to reduce hospital mortality in septic shock patients in intensive care unit. secondary objectives are the resolution of septic shock and the reduction of icu los (length of stay).

Eligibility criteria:
inclusion criteria: * all patients admitted to the icu in septic shock * all patients that develop septic shock while in the icu exclusion criteria: * age less than 14 years * pregnancy * estimated life expectancy (due to comorbidities) less than 90 days * presence of relative or absolute contraindications to cpfa * admission from an other icu where the patient remained for more than 24 hours * absence of informed consent

Keywords: septic shock intensive care medicine coupled plasma filtration-adsorption
acute myeloid leukemia real world treatment patterns

Conditions: Leukemia, Myeloid, Acute

Summary: among patients with a diagnosis of aml who received non-intensive chemotherapy: * describe patient demographic and clinical characteristics * describe treatment patterns * describe effectiveness outcomes * evaluate tumor response


Eligibility criteria:
inclusion criteria: patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. confirmed diagnosis of aml on or after 01 january 2012 through clinical research nurse (crn) review of provider documentation of aml diagnosis in the medical record. 2. receipt of non-intensive therapy at any point during first line therapy following initial aml diagnosis. for this study, non-intensive therapy will be defined as 1 of the following agents, alone or in combination with any other agent: 1. aza 2. glas 3. ven 3. age ≥18 years at initial diagnosis of aml. exclusion criteria: patients meeting any of the following criteria will not be included in the study: 1. record of 1 or more of the following confounding diagnoses at any point before or after aml diagnosis: acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.

Keywords: acute myeloid leukemia (aml)
multicenter study of pharmacokinetic-guided docetaxel in breast cancer patients receiving docetaxel and cyclophosphamide

Conditions: Breast Cancer; Breast Cancer Female

Summary: the purpose of this study is to adjust the amount of docetaxel participants receive based on the level of docetaxel measured in their blood. this method of dose adjustment is called pharmacokinetic (pk)-adjusted docetaxel. the researchers believe that adjusting the dose of docetaxel using this method will lessen the side effects associated with docetaxel in cancer treatment.


Eligibility criteria:
inclusion criteria: * must have histologically confirmed localized or locally advanced breast cancer for which the treatment plan includes chemotherapy with 4 cycles of standard tc (docetaxel 75 mg/m\^2 and cyclophosphamide 600mg/m\^2) * age \>/= 65 years (senior adult focused study given increased risk for toxicity) * participants must be female * eastern cooperative oncology group (ecog) performance status \<2 * must have normal organ and marrow function * no pre-existing neuropathy grade \> 1 per the nci common toxicity criteria for adverse effects (ctcae) version 4.0 * be postmenopausal (defined as amenorrheic for at least 12 months) * must be informed of the investigational nature of this study and be willing to provide written informed consent in accordance with institutional guidelines and good clinical practice (gcp) indicating that they understand the purpose of and procedures required for the study and are willing to participate prior to the beginning of any specific study procedures. exclusion criteria: * have uncontrolled illness (including, but not limited to, ongoing or active infection, congestive heart failure, angina pectoris, or cardiac arrhythmia) that would limit compliance with study requirements * have psychiatric illness that would limit compliance with study requirements * have history of allergic reactions attributed to compounds of similar chemical or biologic composition to taxanes (docetaxel or paclitaxel) or cyclophosphamide * have known seropositivity for human immunodeficiency virus, hepatitis c virus, hepatitis b surface antigen, or syphilis. does not require serologic confirmation as a study procedure. * not willing to follow protocol requirements or to give informed consent

Keywords: senior adult postmenopausal